Toinv - I wouldn't make the assumption that "they are very open at scientific conferences." As Bear said a few days earlier "not much has changed" and yet 3 to 5 months have passed. Remember that this patient that is still with us after 10/11 months of dosing was not expected to live past 90 days. To me that's kind of a wow. What we don't know is how many patients in the mono cohorts are still with us or how many in the combo cohorts have, been recruited? what cohort they are on?and what the experience is for the patients longevity so far in the combination cohorts? If this info that the company has full access to is as good as that of the patient that is still with us from the mono cohort then there is a sellable product here in this Phase I trial. Not having to tell the world about your results because you are private could be an exceptional advantage in a sales process.

I wonder when they are going to move on to the breast cancer leg of this trial?

Remember in the mouse trials they tested ZEN3694 with 30ish different existing cancer drugs in combination and showed better results than those other drugs on their own. How sweat would that be for a BP to own a drug that all of their competitors would help them sell?

tada